An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers

Joana Santos-Gomes; Inês Gandra; Rui Adão; Frédéric Perros; Carmen Brás-Silva

doi:10.3389/fcvm.2022.924873

An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers

Front Cardiovasc Med. 2022 Jul 14:9:924873. doi: 10.3389/fcvm.2022.924873. eCollection 2022.

Authors

Joana Santos-Gomes¹, Inês Gandra¹, Rui Adão¹, Frédéric Perros^{2

3}, Carmen Brás-Silva^{1

4}

Affiliations

¹ UnIC@RISE, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal.
² Paris-Porto Pulmonary Hypertension Collaborative Laboratory (3PH), UMR_S 999, INSERM, Université Paris-Saclay, Paris, France.
³ Université Paris-Saclay, AP-HP, INSERM UMR_S 999, Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital de Bicêtre, Le Kremlin Bicêtre, France.
⁴ Faculty of Nutrition and Food Sciences, University of Porto, Porto, Portugal.

Abstract

Pulmonary arterial hypertension (PAH), also known as Group 1 Pulmonary Hypertension (PH), is a PH subset characterized by pulmonary vascular remodeling and pulmonary arterial obstruction. PAH has an estimated incidence of 15-50 people per million in the United States and Europe, and is associated with high mortality and morbidity, with patients' survival time after diagnosis being only 2.8 years. According to current guidelines, right heart catheterization is the gold standard for diagnostic and prognostic evaluation of PAH patients. However, this technique is highly invasive, so it is not used in routine clinical practice or patient follow-up. Thereby, it is essential to find new non-invasive strategies for evaluating disease progression. Biomarkers can be an effective solution for determining PAH patient prognosis and response to therapy, and aiding in diagnostic efforts, so long as their detection is non-invasive, easy, and objective. This review aims to clarify and describe some of the potential new candidates as circulating biomarkers of PAH.

Keywords: biomarkers; circulating levels; diagnosis; prognosis; pulmonary arterial hypertension; pulmonary hypertension.

Publication types

Review